jurnista 16 mg depottabletter
janssen-cilag a/s - hydromorphonhydrochlorid - depottabletter - 16 mg
jurnista 32 mg depottabletter
janssen-cilag a/s - hydromorphonhydrochlorid - depottabletter - 32 mg
jurnista 8 mg depottabletter
janssen-cilag a/s - hydromorphonhydrochlorid - depottabletter - 8 mg
inter-pirimicarb 50 vanddispergerbart granulat
inter-trade a/s - pirimicarb - vanddispergerbart granulat - 500 g/kg pirimicarb
it-cypermethrin suspensionskoncentrat
inter-trade a/s - cypermethrin - suspensionskoncentrat - 100 g/l cypermethrin
koselugo
astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastiske midler - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.
tepmetko
merck europe b.v. - tepotinib hydrochloride monohydrate - carcinom, ikke-småcellet lunge - antineoplastiske midler - tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (nsclc) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (metex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.
oxis turbuhaler 9 mikrogram/dosis inhalationspulver
astrazeneca a/s - formoterolfumarat dihydrat - inhalationspulver - 9 mikrogram/dosis
sivextro
merck sharp & dohme b.v. - tedizolid phosphat - soft tissue infections; skin diseases, bacterial - antibacterials for systemic use, , other antibacterials - sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (absssi) in adults and adolescents 12 years of age and older.
voriconazole "orion" 200 mg filmovertrukne tabletter
orion corporation - voriconazol - filmovertrukne tabletter - 200 mg